Oxford-Cambridge Innovation Showcase brings leading life sciences spinouts and global investors together in London
25th November 2025
A gathering of investors and life sciences ventures from Oxford and Cambridge showcased the region’s research strengths and its growing impact on global health.
A joint-first event bringing together world-leading Oxford and Cambridge life-sciences spinouts with international investors was held in London last week as part of the Jefferies Healthcare Conference and London Life Sciences Week.
The Oxford-Cambridge Innovation Showcase – a collaboration born from the joint work with the Oxford-Cambridge Growth Corridor – brought together 170 international investors to hear rapid-fire pitches from 20 companies developing technologies in areas such as cancer immunology, antimicrobial resistance, vaccine delivery, and gene and cell therapy. Each company had 90 seconds to pitch its idea to the room.
It was organised by Oxford University Innovation, Cambridge Enterprise and Cambridge University Health Partners to focus on accelerating the translation of research into patient impact and economic growth.
Dr Zubir Ahmed, Parliamentary Under-Secretary of State at the Department of Health and Social Care, spoke about the strength of innovation across the Oxford–Cambridge region.
Cav Elithorn, Director of the Oxford to Cambridge Growth Corridor, highlighted the government’s investment in the Corridor and the future economic and societal benefits it aims to unlock. He also emphasised the importance of the Cowley Branch Line in connecting Oxford’s science parks and supporting regional growth.
Mairi Gibbs, OUI’s CEO, said: ‘With world-leading life sciences spinouts from Oxford and Cambridge brought together with leading international investors, the showcase demonstrated how sustained investment and genuine partnership across the Growth Corridor – combined with world-leading knowledge and research, brilliant ecosystem partners, and a shared determination to tackle global health challenges – can deliver real impact.’
Oxford spinout companies presented included SpyBiotech, AlveoGene, Caristo Diagnostics, Singula Bio, DaltonTx, Oxford Stemtech, Alethio Therapeutics, Orfonyx Bio, Glox Therapeutics, and Pictura Bio.
Cambridge companies represented included DIOSynVax, MabGalaxy, Epitopea, 52 North Health, Camoxis, Trimtech Therapeutics, BaseRx, Cyclana Bio, Enhanced Genomics, and Houdini Bio.
The event was sponsored by Penningtons Manches Cooper and HGF, with additional support from AstraZeneca, Babraham Research Campus, Cambridge Innovation Capital, Wellcome Genome Campus, and the Wellcome Sanger Institute.
Image credits: David Johnson
